Documents
Consultation on the Projected Impact and Cost-Effectiveness of Long-Acting Injectable Lenacapavir as Pre-Exposure Prophylaxis
06 June 2025
Documents
What can modelling tell us about the scale-up of lenacapavir for pre-exposure prophylaxis?
18 September 2025
Scaling up primary HIV prevention, including pre-exposure prophylaxis (PrEP), is essential to closing the prevention gap and reducing the number of new HIV infections, especially as countries approach the 95–95–95 treatment targets1 but continue to face a stagnant or rising incidence of HIV among people from key and priority populations. Injectable lenacapavir is a new long-acting injectable antiretroviral medicine given every six months for HIV prevention. In clinical trials, lenacapavir was found to be safe and effective, with 96–100% reduction in HIV acquisition compared with background rates.
Documents
Executive summary — 2025 Global AIDS Update — AIDS, Crisis and the Power to Transform
10 July 2025
A historic funding crisis is threatening to unravel decades of progress unless countries can make radical shifts to HIV programming and funding. The report highlights the impact that the sudden, large-scale funding cuts from international donors are having on countries most affected by HIV. Yet it also showcases some inspiring examples of resilience, with countries and communities stepping up in the face of adversity to protect the gains made and drive the HIV response forward.
Documents
2025 Global AIDS Update — AIDS, Crisis and the Power to Transform
10 July 2025
A historic funding crisis is threatening to unravel decades of progress unless countries can make radical shifts to HIV programming and funding. The report highlights the impact that the sudden, large-scale funding cuts from international donors are having on countries most affected by HIV. Yet it also showcases some inspiring examples of resilience, with countries and communities stepping up in the face of adversity to protect the gains made and drive the HIV response forward.
Documents
The cost of inaction: The cost of not realizing the sexual and reproductive health and rights (including HIV) of young people in Zimbabwe and South Africa
02 June 2025
UNAIDS uses ‘cost of inaction’ as an indicator of the negative impact on the lives of people and communities of not investing resources to end AIDS. This issue is particularly significant with regard to the provision of sexual and reproductive health and rights (SRHR) and HIV services for young people in eastern and southern Africa.
The cost of inaction for young people is especially significant as the impact extends through most of their life. This report explores the costs of inaction in not realising the SRHR needs of young people in South Africa and Zimbabwe, focusing on costs related to: 1) adolescent pregnancies, 2) HIV acquisition and 3) gender-based violation.
Using a cost of inaction approach, this report calculates the current cost of the inadequate provision of SRHR and HIV services to young people aged 15–24 years old in the two countries. This provides a foundation for alternative policies to be costed to address these gaps and a true cost–benefit analysis to be conducted.